REGN · Plain-English company overview
A stock is a share of ownership in a company. Owning one means you own a small piece of that business.
In the company's own words, from Item 1 (Business) of its latest annual report (Form 10-K) filed with the SEC on 2026-02-04.
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Our products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Our core business strategy is to maintain a strong foundation in scientific research and drug development using our proprietary technologies, and to build on that foundation with our clinical development, manufacturing, and commercial capabilities. Our objective is to continue to advance as an integrated, multi-product biotechnology company that provides patients and medical professionals with important medicines for preventing and treating human diseases.
Read the full 10-K on SEC.gov →
An earnings release is a company's quarterly report of how much money it made. Analysts predict these numbers ahead of time, and the actual results are compared against those predictions.
In the most recent quarter (2026-06-30), Regeneron Pharmaceuticals reported earnings of $14.29 per share. Analysts expected $10.4682 per share, so the company beat expectations.
Zelothorn provides plain-English summaries drawn from official SEC filings for educational purposes only. It is not financial advice and does not recommend buying or selling any security.